Traders should monitor for downward pressure on DNTH shares, especially given the concentration of sales among top executives. Absent offsetting positive news, this level of insider selling may signal lack of confidence at the leadership level.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 12 $80.32entry
- T+1 · 8mo ago −3.06%α −2.47% · $77.86
- T+5 · 8mo ago −0.40%α +0.58% · $80.00
- T+20 · 7mo ago +11.77%α +9.79% · $89.77
- T+60 · 5mo ago +0.24%α −10.46% · $80.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three Dianthus Therapeutics executives, including the CEO and EVP of R&D, exercised stock options and sold shares in the open market, collectively realizing over $7.5 million in proceeds. The sales represent a coordinated monetization of equity, with the CEO alone selling $3.5 million worth of stock.
Key Financial Metrics
Key Facts
- CEO Garcia Marino sold 43,505 shares for $3.51 million after exercising options totaling 122,918 shares.
- EVP Randhawa sold 33,830 shares for $2.76 million following option exercises.
- Chief Accounting Officer Carr sold 15,852 shares for $1.28 million.
- Total open-market sales by insiders: $7.53 million in one day.
- All transactions occurred on 2026-03-12, indicating a coordinated cluster.
Financial Impact
$7.53 million in insider sales, representing 0.21% of Dianthus's $3.6B market cap
Risk Factors
- Perception of insider pessimism ahead of key clinical or financing events
- Potential for follow-on selling or secondary offerings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (9 trades, 7d window) | cluster-DNTH-1773448232345 |
Track record
23 reports on DNTH
6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers